Monograph
C03AA03 - Hydrochlorothiazide |
Propably not porphyrinogenic |
PNP |
Rationale
CAVE: Under revision. Clinical experience of non-porphyrinogenicity. Conflicting references, but several references refer to hydrochlorothiazide as safe in acute porphyrias. Hydrochlorothiazide is a sulfonamide congener, but apart from this there are no indications of porphyrinogenicity. Hydrochlorothiazide is not metabolised in the liver and has probably no CYP450 affinity.
Chemical description
Sulfonamide congener.
Therapeutic characteristics
Thiazide diuretic.
Metabolism and pharmacokinetics
Probably no CYP-affinity. Eliminated mainly unchanged in the urine. Seemingly not appreciably metabolized.
Preclinical data
AWAITING (Anderson 1981)
Personal communication
Thunell, patient report (n=1): tolerated. Andersson, patient reports (n=10): tolerated. Peters: On basis of clinical experience probably not porphyrinogenic.
IPNet drug reports
Uneventful use reported in 9 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Induction of hepatic delta-aminolevulinate synthase and cytochrome P-450 by a thiazide diuretic. [Journal] Hepatology. Vol. 1(5)(pp 1A), 1981.
Anderson KE. Kappas A. |
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Poland
Iceland
Finland
Latvia
Serbia
